Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGND) Operating Leases (2019 - 2025)

Historic Operating Leases for Ligand Pharmaceuticals (LGND) over the last 7 years, with Q3 2025 value amounting to $4.4 million.

  • Ligand Pharmaceuticals' Operating Leases fell 2955.16% to $4.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.4 million, marking a year-over-year decrease of 2955.16%. This contributed to the annual value of $5.8 million for FY2024, which is 596.7% down from last year.
  • Per Ligand Pharmaceuticals' latest filing, its Operating Leases stood at $4.4 million for Q3 2025, which was down 2955.16% from $4.6 million recorded in Q2 2025.
  • Over the past 5 years, Ligand Pharmaceuticals' Operating Leases peaked at $37.3 million during Q3 2022, and registered a low of $3.6 million during Q1 2025.
  • Over the past 5 years, Ligand Pharmaceuticals' median Operating Leases value was $6.2 million (recorded in 2023), while the average stood at $10.3 million.
  • As far as peak fluctuations go, Ligand Pharmaceuticals' Operating Leases soared by 52179.84% in 2022, and later tumbled by 8436.46% in 2023.
  • Over the past 5 years, Ligand Pharmaceuticals' Operating Leases (Quarter) stood at $3.7 million in 2021, then surged by 196.65% to $11.1 million in 2022, then plummeted by 44.07% to $6.2 million in 2023, then decreased by 5.97% to $5.8 million in 2024, then fell by 24.08% to $4.4 million in 2025.
  • Its last three reported values are $4.4 million in Q3 2025, $4.6 million for Q2 2025, and $3.6 million during Q1 2025.